JP2024504260A - セリンおよびグリシンの制限の調節およびそれらの制限に対する感受性化のための方法 - Google Patents

セリンおよびグリシンの制限の調節およびそれらの制限に対する感受性化のための方法 Download PDF

Info

Publication number
JP2024504260A
JP2024504260A JP2023537587A JP2023537587A JP2024504260A JP 2024504260 A JP2024504260 A JP 2024504260A JP 2023537587 A JP2023537587 A JP 2023537587A JP 2023537587 A JP2023537587 A JP 2023537587A JP 2024504260 A JP2024504260 A JP 2024504260A
Authority
JP
Japan
Prior art keywords
cells
serine
cancer
glycine
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023537587A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024504260A5 (https=
Inventor
オリバー ディー． ケー． マドックス
カレン ボーデン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Technology Ltd
Original Assignee
Cancer Research Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Technology Ltd filed Critical Cancer Research Technology Ltd
Publication of JP2024504260A publication Critical patent/JP2024504260A/ja
Publication of JP2024504260A5 publication Critical patent/JP2024504260A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1042—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy with spatial modulation of the radiation beam within the treatment head
    • A61N5/1045—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy with spatial modulation of the radiation beam within the treatment head using a multi-leaf collimator, e.g. for intensity modulated radiation therapy or IMRT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Chemical Or Physical Treatment Of Fibers (AREA)
JP2023537587A 2020-12-16 2021-12-15 セリンおよびグリシンの制限の調節およびそれらの制限に対する感受性化のための方法 Pending JP2024504260A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063126294P 2020-12-16 2020-12-16
US63/126,294 2020-12-16
US202163168414P 2021-03-31 2021-03-31
US63/168,414 2021-03-31
US202163170805P 2021-04-05 2021-04-05
US63/170,805 2021-04-05
PCT/US2021/063639 WO2022132981A1 (en) 2020-12-16 2021-12-15 Methods for modulation of and sensitization to serine and glycine limitation

Publications (2)

Publication Number Publication Date
JP2024504260A true JP2024504260A (ja) 2024-01-31
JP2024504260A5 JP2024504260A5 (https=) 2024-12-20

Family

ID=82023934

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023537587A Pending JP2024504260A (ja) 2020-12-16 2021-12-15 セリンおよびグリシンの制限の調節およびそれらの制限に対する感受性化のための方法

Country Status (6)

Country Link
US (1) US20220193447A1 (https=)
EP (1) EP4262787A4 (https=)
JP (1) JP2024504260A (https=)
AU (1) AU2021403024A1 (https=)
CA (1) CA3205385A1 (https=)
WO (1) WO2022132981A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109069462A (zh) 2016-02-23 2018-12-21 癌症研究科技有限公司 缺乏至少两种非必需氨基酸的膳食产品
JP2023530235A (ja) 2020-06-03 2023-07-14 フェス・セラピューティクス，インコーポレーテッド 個別化された処置方法のための製剤
WO2021247923A1 (en) 2020-06-04 2021-12-09 Faeth Therapeutics, Inc. Personalized methods of treating cancer
WO2025029650A1 (en) 2023-07-28 2025-02-06 Li Xiyan Nutritionally modified diets comprising aminoacids for use in treating a disease
WO2025208086A1 (en) * 2024-03-29 2025-10-02 Faeth Therapeutics, Inc. Dietary regimens and methods for treatment of colorectal cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019507754A (ja) * 2016-02-23 2019-03-22 キャンサー・リサーチ・テクノロジー・リミテッドＣａｎｃｅｒ Ｒｅｓｅａｒｃｈ Ｔｅｃｈｎｏｌｏｇｙ Ｌｉｍｉｔｅｄ 少なくとも２つの非必須アミノ酸を欠くダイエタリー製品

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107921133A (zh) * 2015-09-04 2018-04-17 国立大学法人大阪大学 癌症的饮食疗法开发
JP7623784B2 (ja) * 2016-10-13 2025-01-29 ジュノー セラピューティクス インコーポレイテッド トリプトファン代謝経路調節剤を含む免疫療法の方法および組成物
CA3119300A1 (en) * 2017-11-13 2019-05-16 Cancer Research Technology Ltd. Dietary product
WO2021247923A1 (en) * 2020-06-04 2021-12-09 Faeth Therapeutics, Inc. Personalized methods of treating cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019507754A (ja) * 2016-02-23 2019-03-22 キャンサー・リサーチ・テクノロジー・リミテッドＣａｎｃｅｒ Ｒｅｓｅａｒｃｈ Ｔｅｃｈｎｏｌｏｇｙ Ｌｉｍｉｔｅｄ 少なくとも２つの非必須アミノ酸を欠くダイエタリー製品

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CANCERS, vol. 13, no. 1191, JPN6026001330, 10 March 2021 (2021-03-10), pages 1 - 25, ISSN: 0005773394 *
NATURE, vol. 544, JPN6026001329, 2017, pages 372 - 376, ISSN: 0005773393 *

Also Published As

Publication number Publication date
EP4262787A4 (en) 2024-11-13
AU2021403024A9 (en) 2024-10-31
CA3205385A1 (en) 2022-06-23
WO2022132981A1 (en) 2022-06-23
AU2021403024A1 (en) 2023-06-29
EP4262787A1 (en) 2023-10-25
US20220193447A1 (en) 2022-06-23

Similar Documents

Publication Publication Date Title
JP2024504260A (ja) セリンおよびグリシンの制限の調節およびそれらの制限に対する感受性化のための方法
US11040052B2 (en) Methods and pharmaceutical compositions for modulating autophagy in a subject in need thereof
Cordova et al. GCN2 eIF2 kinase promotes prostate cancer by maintaining amino acid homeostasis
US10772862B2 (en) Lipid scavenging in Ras cancers
JP2019507754A (ja) 少なくとも２つの非必須アミノ酸を欠くダイエタリー製品
US12109184B2 (en) Personalized methods of treating cancer
US11872230B2 (en) Method of treating a methionine-dependent cancer
WO2025184572A1 (en) Wee1 inhibitor combination therapy
US20220347125A1 (en) Antitumor agent and compounding agent
US20250127783A1 (en) Inhibitors of the peptidyl-prolyl cis/trans isomerase (pin1), combinations and uses thereof
CN116916915A (zh) 用于调节和针对丝氨酸和甘氨酸限制进行敏化的方法
Li et al. Nintedanib enhances tumor cell radiosensitivity by promoting ferroptosis and modulating the ATF4/SLC7A11/GSH axis
Conger Identification of ASCT2 as the Primary Serine Transporter in Cancer
US20230346831A1 (en) Methods for treating metastatic cancer using low dose carbon monoxide
Esperança-Martins et al. Sarcoma Metabolomics: Current Horizons and Future Perspectives. Cells. 2021; 10: 1432
Luttman Exploiting Metabolic Vulnerabilities In Solid Tumors Treated With ABL Kinase Allosteric Inhibitors
Khalifa PERIODIC FASTING AS A TOOL FOR DRUG REPURPOSING: ENHANCEMENT OF CHOLESTEROL BIOSYNTHESIS INHIBITORS ANTITUMOR EFFECTS VIA DIETARY RESTRICTION
Baker The role of the core autophagy gene ATG3 in leukemia cell survival and metabolism
Xu THE ROLE OF GLUTAMATE METABOLISM IN REGULATING CD4+ AND CD8+ T CELL DIFFERENTIATION
Jun Investigating the Therapeutic Potential of L-asparaginase in Myeloid Leukemia
Gabra Adaptations to Glutamine Deprivation in Cancer and Its Use as a Dietary Supplement in Cancer Therapeutics
Ramirez Starving cancer: the molecular mechanisms of nutrient transporter loss induced by anti-neoplastic sphingolipids
Chen Role of autophagy in cancer
Banh Novel Metabolic Dependencies in Cancer and Moyamoya Disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230817

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241212

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260416